Divis Laboratories, a key player in the pharmaceutical sector, reported a 13.4% year-on-year increase in consolidated net profit, reaching ₹751 crore for the fourth quarter of fiscal year 2026 (Q4 FY26). This growth was accompanied by a 9.52% rise in revenue from operations, totaling ₹2,831 crore compared to ₹2,585 crore in Q4 FY25. The profit before tax (PBT) also saw a significant increase of 11.46%, amounting to ₹963 crore. However, total expenses rose by 11.95% to ₹2,023 crore, primarily driven by a 30.4% increase in material costs, which reached ₹1,214 crore. Additionally, the company benefited from a forex gain of ₹90 crore in Q4 FY26, a notable increase from ₹10 crore in the same quarter last year. For the full fiscal year, Divis Laboratories reported a consolidated net profit of ₹2,568 crore, reflecting a 17.21% increase, and a revenue growth of 12.82% to ₹10,560 crore. The board has recommended a final dividend of ₹30 per equity share, pending approval at the 36th Annual General Meeting scheduled for August 10, 2026.